Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 03:32 pm IST
Share
Honz Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 586.14 million compared to CNY 631.91 million a year ago. Revenue was CNY 586.14 million compared to CNY 631.91 million a year ago. Net loss was CNY 41.61 million compared to net income of CNY 2.13 million a year ago. Basic loss per share from continuing operations was CNY 0.0925 compared to basic earnings per share from continuing operations of CNY 0.0047 a year ago. Diluted loss per share from continuing operations was CNY 0.0925 compared to diluted earnings per share from continuing operations of CNY 0.0047 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.